This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AVANIR Pharmaceuticals (AVNR)

NASDAQ: Health Care

Company Cash Flow
Sep 2013 Sep 2012 Sep 2011 Sep 2010
Cash Flow From Operating Activities
Net Income (Loss) -75.48M -59.74M -60.63M -26.69M
Operating Gains/Losses 279.00 0.00 9.27K 0.00
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -5.50M -5.22M -2.01M 0.00
(Increase) Decrease in Inventories -170.53K -278.66K -164.34K -56.21K
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 2.89M -327.63K 1.29M 761.37K
(Decrease) Increase In Other Current Liabilities 7.64M 6.07M 3.71M 551.85K
(Increase) Decrease In Other Working Capital -2.76M -3.74M -685.42K -1.44M
Other Non-Cash Items 6.05M 4.88M 3.78M 2.75M
Net Cash From Continuing Operations -65.42M -57.66M -56.52M -23.80M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -65.42M -57.66M -56.52M -23.80M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 401.55K 0.00 0.00 66.92K
Purchases of Property, Plant & Equipment -448.30K -813.00K -1.82M -213.41K
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments 0.00 0.00 0.00 -200.00K
Other Cash from Investing Activities -314.88K 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -361.62K -916.66K -3.47M -346.49K
Issuance of Debt 0.00 29.61M 0.00 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 51.26M 19.19M 100.19M 31.64M
Repayment of Long-Term Debt 0.00 0.00 0.00 0.00
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 0.00 0.00 575.24K -212.66K
Net Cash From Financing Activities 51.26M 48.81M 100.77M 31.43M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents -14.52M -9.76M 40.77M 7.29M
AVNR News

AVNR AVANIR Pharmaceuticals

Analysts Ratings for AVNR

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 2 2 3 3
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET AVNR ANALYST REPORT

Brokerage Partners

AVNR Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs